We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study.
- Authors
Se Ik Kim; Hyunji Lim; Hee Seung Kim; Hyun Hoon Chung; Jae-Weon Kim; Noh Hyun Park; Yong-Sang Song; Maria Lee
- Abstract
Purpose This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinumsensitive relapsed (PSR) epithelial ovarian cancer (EOC). Materials and Methods We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice. Results Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992). Conclusion In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.
- Subjects
CANCER relapse; SURVIVAL rate; CYTOREDUCTIVE surgery; OVARIAN cancer; OVARIAN epithelial cancer
- Publication
Cancer Research & Treatment, 2023, Vol 55, Issue 1, p245
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2022.232